Published in Lancet on September 26, 2005
Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis (2006) 7.64
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother (2009) 6.33
Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ (2005) 5.59
Toxin B is essential for virulence of Clostridium difficile. Nature (2009) 5.49
The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev (2010) 4.48
Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis (2012) 4.34
Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet (2012) 4.10
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog (2012) 3.81
Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol (2009) 3.66
Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol (2008) 3.21
Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis (2013) 3.15
Current status of Clostridium difficile infection epidemiology. Clin Infect Dis (2012) 3.14
Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg (2007) 3.08
Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol (2006) 3.05
Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol (2007) 2.77
Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52
tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49
Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol (2010) 2.47
Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol (2010) 2.29
Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent) (2006) 2.26
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis (2013) 2.22
Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol (2006) 2.18
Clostridium difficile in retail ground meat, Canada. Emerg Infect Dis (2007) 2.17
Clostridium difficile PCR ribotypes in calves, Canada. Emerg Infect Dis (2006) 2.12
Dentists, antibiotics and Clostridium difficile-associated disease. Br Dent J (2015) 2.10
A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis (2013) 2.08
Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS One (2011) 2.04
The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun (2012) 2.02
Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol (2008) 1.98
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol (2009) 1.97
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis (2012) 1.96
Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis (2009) 1.95
Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One (2008) 1.88
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother (2008) 1.84
Morphological and genetic diversity of temperate phages in Clostridium difficile. Appl Environ Microbiol (2007) 1.71
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother (2008) 1.71
Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl Environ Microbiol (2012) 1.70
Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J Clin Microbiol (2012) 1.54
Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis (2010) 1.53
Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis (2006) 1.52
Evaluation of the Cepheid Xpert Clostridium difficile Epi assay for diagnosis of Clostridium difficile infection and typing of the NAP1 strain at a cancer hospital. J Clin Microbiol (2010) 1.49
Rapid molecular characterization of Clostridium difficile and assessment of populations of C. difficile in stool specimens. J Clin Microbiol (2009) 1.48
Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med (2011) 1.48
Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int (2014) 1.47
Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol (2012) 1.47
Identification of risk factors for the development of clostridium difficile-associated diarrhea following treatment of polymicrobial surgical infections. Ann Surg (2010) 1.47
Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol (2008) 1.47
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology (2015) 1.42
First report of Clostridium difficile NAP1/027 in a Mexican hospital. PLoS One (2015) 1.40
The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes (2010) 1.37
Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol (2011) 1.37
SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J Bacteriol (2009) 1.35
Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect Immun (2009) 1.35
Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol (2012) 1.34
Clostridium difficile infection: a worldwide disease. Gut Liver (2014) 1.33
NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis (2014) 1.31
Spores of Clostridium difficile clinical isolates display a diverse germination response to bile salts. PLoS One (2012) 1.31
Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. J Clin Microbiol (2009) 1.30
Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS One (2011) 1.29
Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis (2007) 1.29
Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol (2007) 1.29
The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog (2011) 1.28
Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog (2010) 1.26
Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One (2011) 1.24
Incidence and Costs of Clostridium difficile Infections in Canada. Open Forum Infect Dis (2015) 1.22
Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One (2013) 1.22
Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol (2012) 1.22
Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist (2014) 1.21
Clostridium difficile toxins: mediators of inflammation. J Innate Immun (2012) 1.21
gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis (2007) 1.20
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19
Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis (2011) 1.18
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol (2007) 1.17
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Antimicrobial resistance in hospitals: how concerned should we be? CMAJ (2009) 1.16
The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe (2013) 1.14
Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerg Infect Dis (2010) 1.13
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Diarrhea, clostridium difficile, and intestinal inflammation in residents of a long-term care facility. J Am Med Dir Assoc (2010) 1.11
Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. J Bacteriol (2011) 1.10
Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother (2011) 1.10
Epidemiology of Clostridium difficile infection. J Pharm Pract (2013) 1.10
Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol (2013) 1.10
Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis (2009) 1.10
Proline-dependent regulation of Clostridium difficile Stickland metabolism. J Bacteriol (2012) 1.09
Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis (2012) 1.09
Analysis of proline reduction in the nosocomial pathogen Clostridium difficile. J Bacteriol (2006) 1.09
Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun (2011) 1.09
Clostridium difficile infection in the twenty-first century. Emerg Microbes Infect (2013) 1.09
Bench-to-bedside review: Clostridium difficile colitis. Crit Care (2008) 1.08
Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol (2011) 1.08
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med (2011) 1.08
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol (2010) 17.99
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis (2005) 6.78
A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med (2005) 6.14
Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol (2006) 5.97
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis (2004) 5.67
Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis (2008) 5.41
Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA (2010) 4.74
Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis (2005) 4.52
Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet (2012) 4.10
Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis (2008) 3.95
Transactional sex is the driving force in the dynamics of HIV in Accra, Ghana. AIDS (2004) 3.87
Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother (2004) 3.44
Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis (2007) 3.21
Current status of Clostridium difficile infection epidemiology. Clin Infect Dis (2012) 3.14
An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis (2006) 2.98
Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis (2006) 2.79
Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med (2013) 2.78
Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis (2008) 2.61
Detection of mecA-mediated resistance using reference and commercial testing methods in a collection of Staphylococcus aureus expressing borderline oxacillin MICs. Diagn Microbiol Infect Dis (2007) 2.48
Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis (2006) 2.43
The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis (2012) 2.34
ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis (2006) 2.27
Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis (2009) 2.24
Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan. Antimicrob Agents Chemother (2007) 2.01
Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect Control Hosp Epidemiol (2009) 2.00
Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis (2008) 1.98
Emergence of community-associated methicillin resistant Staphylococcus aureus in Hawaii, 2001-2003. J Infect (2006) 1.98
Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med (2006) 1.91
A randomized trial of the impact of multiple micronutrient supplementation on mortality among HIV-infected individuals living in Bangkok. AIDS (2003) 1.79
National estimates of central line-associated bloodstream infections in critical care patients. Infect Control Hosp Epidemiol (2013) 1.69
Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis (2008) 1.67
The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis (2007) 1.66
Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol (2009) 1.63
Necrotizing enterocolitis associated with clostridium perfringens type A in previously healthy north american adults. J Am Coll Surg (2005) 1.58
A national survey of severe influenza-associated complications among children and adults, 2003-2004. Clin Infect Dis (2005) 1.56
Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis (2005) 1.56
Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis (2009) 1.55
Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis (2010) 1.53
Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch Intern Med (2007) 1.50
Wrestling SARS from uncertainty. Emerg Infect Dis (2004) 1.50
Iatrogenic transmission of human T cell lymphotropic virus type 1 and hepatitis C virus through parenteral treatment and chemoprophylaxis of sleeping sickness in colonial Equatorial Africa. Clin Infect Dis (2010) 1.49
Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS (2007) 1.48
Multilocus sequence typing of Campylobacter jejuni isolates from humans, chickens, raw milk, and environmental water in Quebec, Canada. J Clin Microbiol (2008) 1.46
Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005. Infect Control Hosp Epidemiol (2008) 1.45
Possible SARS coronavirus transmission during cardiopulmonary resuscitation. Emerg Infect Dis (2004) 1.45
Host cell invasion and virulence mediated by Candida albicans Ssa1. PLoS Pathog (2010) 1.43
Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol (2009) 1.38
A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med (2011) 1.38
Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control (2007) 1.35
A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med (2006) 1.34
Vancomycin-resistant enterococci from humans and retail chickens in Taiwan with unique VanB phenotype-vanA genotype incongruence. Antimicrob Agents Chemother (2002) 1.31
The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis (2008) 1.31
Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. Infect Control Hosp Epidemiol (2010) 1.29
Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol (2006) 1.26
Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis (2011) 1.26
Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol (2008) 1.25
Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol (2008) 1.24
Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol (2007) 1.23
Multicenter study of the impact of community-onset Clostridium difficile infection on surveillance for C. difficile infection. Infect Control Hosp Epidemiol (2009) 1.23
Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J Gen Virol (2009) 1.21
A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis (2007) 1.20
Synergistic interaction between Candida albicans and commensal oral streptococci in a novel in vitro mucosal model. Infect Immun (2011) 1.20
Role of Bcr1-activated genes Hwp1 and Hyr1 in Candida albicans oral mucosal biofilms and neutrophil evasion. PLoS One (2011) 1.20
Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS One (2012) 1.19
Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol (2008) 1.18
Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J Clin Microbiol (2005) 1.15
Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis (2009) 1.14
The complex vaginal flora of West African women with bacterial vaginosis. PLoS One (2011) 1.13
Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol (2005) 1.10
Bench-to-bedside review: Clostridium difficile colitis. Crit Care (2008) 1.08
Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol (2007) 1.08
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol (2007) 1.08
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 1.07
Clostridium difficile infections in children. Pediatr Infect Dis J (2009) 1.07
Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol (2011) 1.05
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis (2010) 1.04
Lack of SARS transmission among healthcare workers, United States. Emerg Infect Dis (2004) 1.04
Factors of the psychopathic personality inventory: criterion-related validity and relationship to the BIS/BAS and five-factor models of personality. Assessment (2008) 1.03
Clostridium difficile strains from community-associated infections. J Clin Microbiol (2009) 1.03
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis (2013) 1.03
Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest (2003) 1.02
Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One (2010) 1.01